Index

Editorials, Letters to the Editor, Case Reports and Short Reports are indicated by (E), (L), (CR) and (SR) - after the page numbers, respectively

Aalderen WMC van 102-7 Abe K 13840 (CR) Abe S 891-7 Abisheganaden J 277-82 acetic acid, cough response to 58-61 ADAi/ADAp ratio in pleural TB 816-21 aerobic capacity limitation in ankylosing spondylitis 700-8 Agostinis L 709-14 Agusti AGN 739-43 Ahlner J 584-8 airway

diseases, bronchial brushing safety and cellular assess- ment 461-6

inflammation evaluation in hyper-responsive cross-coun- try skiers and asthmatics 719-25

obstruction, bronchodilator response 630-6 responsiveness and atopy in asthma, nitric oxide exhala-

tion relationship to 552-6 subepithelial tenascin in asthma, albuterol and nedocro-

mil sodium effects on 445-53 Akkaya V 119-22 albuterol effects on airway subepithelial tenascin in asthma

445-53 Almqvist G 491-7 Alsbach GPJ 46-51 altitude effects on lung function 73943 Altraja A 445-53 alveolar macrophages in lung cancer, interleukin-10 pro-

duction by 666-71 amiodarone lung and emphysema, spirometry normal-

ization in 597-600 (CR) Anderson TJ 23644, 370 (erratum), (erratum end July

issue) Andersson B 563-70 Andersson T 79-87 Ando M 4324 (SC) androgens in obstructive sleep apnoea, effects of CPAP on

l-7 Androutsos G 52-7 ankylosing spondylitis, aerobic capcity limitation 700-8 Antczak A 389-96 antibiotic

pre-admission effect on blood cultures in community- acquired pneumonia 208-12

prophylaxis and Aspergillus colonization in cystic fibrosis patients 835-8

therapy inhalation in bronchiectasis and chronic bron- chial infection by Ps. aeruginosa 47&80

alphai-antichymotrypsin mutations in patients with COPD 648-54

antitrypsin (alphai) deficiency, in Italy 169-72 management in COPD 481-90

TAQ I polymorphism in patients with COPD 648-54 Anto JM 822-6 Aotsuka S 955101 arterial oxygenation, nostril widening and 1345 (SR) Art& M 173-9 Arva E 563-70 Arvidsson M 734-8 asbestos exposure in environment, malignant mesothelioma

and 349-55 Aspergillus colonization in cystic fibrosis patients, prophy-

lactic antibiotic therapy and 835-8 Aspergillus terreus, bronchocentric granulomatosis from

6724 (CR) asthma

acute adult, severity and management compared to BTS guidelines 8-10

adolescent 677-84 adult, inhaled corticosteroids for 149-60 airway inflammation evaluation in hyper-responsive

cross-country skiers and 719-25 albuterol and nedocromil sodium effects on airway

subepithelial tenascin 445-53 attacks, treatment by doctors audit 397401 bambuterol vs salmeterol for nocturnal symptoms in

33-8 beclomethasone dipropionate safety in CFC-free propel-

lant system in 27-32 targeting to lungs with Spacehaler 42431 with non-CFC propellant 2445 1

beta-agonists 23643, 370 (erratum), (erratum end July issue)

bronchodilator response in airway obstruction 630-6 budesonide via Turbuhaler 230-5 compliance 763-9 corticosteroid-dependent, eosinophilic inflammation in

183-9 corticosteroid therapy 141-6 (L), 2924 (L) cost-effectiveness of fluticasone propionate and budeso-

nide 402-7 deaths, co-morbidity and diagnostic inaccuracy 923-7 exercise-induced respiratory symptoms 7348 fluticasone propionate vs. budesonide effect on lung

function and exacerbations 6 13-20 health beliefs and compliance with inhaled corticoster-

oids 88-94 house moves, air and heating conditions effects in

children 9 19-22 in elderly 146 (L) induced sputum vs blood monitoring for nitric oxide

metabolites 912-18 inflammatory markers in acute exacerbations of 744-51 medical costs in Netherlands 779-87 mometasone furoate dry powder inhaler for 603-12

INDEX

morbidity index related to fright and bother ideas in community 5 15-l 9

nitric oxide exhalation relationship to airway responsive- ness and atopy in 5522-6

nurse practice 584-8 patient education for self-management 283-9 pharmceutically-based severity startification 788-93 prevalence in Asians in UK 1620

in Finland 798-809 review 85 l-5 salmeterol and need for inhaled corticosteroid in 863-8 serum leptin in children treated with inhaled budesonide

268-7 1 severe chronic, nebulized fluticasone propionate 689-99 severity marker, methacholine-induced fall in FEC

277-82 spirometry and tracheal auscultation agreement in

bronchial responsiveness in 102-7 steroid-dependent, salmeterol/fluticasone propionate in-

haler for 876-84 therapy, patient compliance 856-62 urinary eicosanoids as marker for clinical response to

thromboxane A2 receptor antagonist in 891-7 vs. COPD mortality in emergency room 822-6 work-related, in aircraft engine mechanic 69-70 (CR)

atopy in asthma, nitric oxide exhalation relationship to airway responsiveness and 552-6

Aubier M .876-84 Ayres JG 27-32, 69-70 (CR), 726-33 Azuma A 752-3 (SC)

Badur S 119-22 BAL see bronchial alveolar lavage Balbi B 169-72 bambuterol vs. salmeterol for nocturnal symptoms in

asthma 33-8 Bando M 507-14 Banham SW 700-8 Barbierato SB 262-7 Bargon J 835-8 Barnacle H 689-99 Barnes N 145-6 (L) Barnes NC 402-7 Barry PW 167-8 Bateman N 759-62 Baumelou E 65-8 (CR) Baumer JH 919-22 Baykul C 349-55 Beccaria M 169-12 beclomethasone dipropionate

inhalation 366-9 (L) new preparation 149-60 safety in CFC-free propellant system in asthma 27-32 targeting to lungs of asthmatics with Spacehaler 424-31 with non-CFC propellant in asthma 244-51

Bednall R 759-62 I Beelen RJH 262-7 Benetazzo MG 648-54 Benfield TL 373-8 Benvenuti A 3945

Berger M 88-94 Berkman N 338-41 Berkowitz RB 603-12 Bernstein DI 603-12 Berrill WT 923-7 Berrisoul F 252-61 beta-agonists

for asthma 23&43, 370 (erratum), (erratum end July issue)

for COPD 227-9 -induced inhibition of neutrophil chemotaxis, effect on

LFA-1 and Mac-l expression and polymorpho- nuclear leukocyte antibacterial activity 416-23

beta*-agonists, inhaled long-acting, user characteristics in Southern Europe 709-14

beta-blockers worsening of obstructive sleep apnoea 290 CL)

Bialasiewicz P 389-96 Bisgaard H 144-5 (L) Bitsakou C 52-7 Bjgrneman P 734-8 Bjermer L 719-25 Bjijrnsson E 744-51 Blaive B 33-8 Blomqvist P 23&5 blood gas measurements, capillary, effects of time delay and

temperature 794-7 blood-patch pleurodesis for secondary spontaneous pneu-

mothorax with persistent air leak 432-4 (SC) Boe J 467-73 Boldy DAR 72633 Bombieri C 648-54 Bone D 898-902 Boniface DR 794-7 Bonizzato A 869-74 Boom S van den 643-7 Borderas L 739-43 Boulet LP 613-20 Bousquet J 183-9, 461-6 Bowie PE 361-5 brain natriuretic peptide levels in chronic respiratory failure

with car pulmonale 507-14 Brant LJ 382-8 Bratel T 1-7, 79-87 breath alcohol levels following new formulation metered

dose inhaler use 167-8 breathing techniques, active cycle 660-5 Breitenstein E 810-15 Breuer R 33841 Bromly CL 923-7 bronchial alveolar lavage (BAL)

cell profiles in Wegenr’s granulomatosis 498-506 cytology to detect non-infectious conditions in ITU ’ 571-8

vs. induced sputum for evaluation of sarcoidosis and non-granulomatous interstitial lung disease 827-34

vs. lymphocyte activation markers in blood and bron- chial biopsies and 563-70

bronchial biopsies vs. lymphocyte activation markers in blood and BAL 563-70

INDEX

Carlstrom K l-7 Carter R 700-8 Casan P 73943 Castellani C 869-74 Castellsague J 709-14 catecholamines in obstructive sleep apnoea, effects of

CPAP on l-7 Cattaruzi C 709-14 Caubarrere I 65-8 (CR) Causey AL 18&2 Cazzola M 227-9 (E), 909-l 1 Cecins NM 660-5 Cederlund K 898-902 Chalmers GW 202-7 Chambers CV 88894 Chambers DC 726-33 Champel F 33-8 Chan-Yeung M 39945 Chanez P 183-9, 4616, 763-9 Chaou W-T 83941 (CR) Chee CBE 277782 Chen C-C 277-82 Chen S-J 83941 (CR) Chervisnky P 603312 Chiu I-S 83941 (CR) Choi I-S 912-18 chronic obstructive pulmonary disease see COPD ciprofloxacin suspension efficacy vs co-amoxiclav tablets in

chronic bronchitis 252-61 citric acid, cough response to 58-61 Clark N 85662 Cleary R 515-19 co-amoxiclav tablets efficacy vs. ciprofloxacin suspension in

chronic bronchitis 252-61 Cobben NAM 571-8 Cochrane GM 763-9 Cockcroft DW 5977600 (CR) codeine phosphate premeditation role in bronchoscpy

under local anaesthesia and midazolam sedation 413-15

Cooper CB 71-2 (L) Cooray JHL 655-9 COPD

alpha- 1 -antitrypsin deficiency management 48 l-90 TAQ I polymorphism and alphai-antichymotrypsin

mutations in patients with 648-54 beta-agonists 227-9 bronchodilator response in airway obstruction 630-6 ~ compliance with long-term oxygen therapy 333-7 Finnish National Guidelines for prevention and treat-

ment 1998-2007 297-332 inflammatory markers in acute exacerbations of 74451 inhaled /3-adrenergic or anticholinergic agent and gas

exchange in 222-3 (L) lung-specific health status measure in outpatients 467-73’ medical costs in Netherlands 779-87 nocturnal oxygen desaturation predictors 202-7 oropharyngeal Gram-negative bacillary carriage in 540-5 oxitropium bromide dose effect on formoterol-induced

bronchodilation in 909-l 1

bronchial brushing safety and cellular assessment in airways diseases 461-6

bronchial hyperresponsiveness, serum ECP and urinary LTE4 relationships to 589-96

bronchial infection by Ps. aeruginosa, antibiotic therapy inhalation 476-80

bronchial responsiveness in asthma, spirometry and tra- cheal auscultation agreement in 102-7

bronchiectasis, antibiotic therapy inhalation in 476-80 bronchiolitis, respiratory syncytial virus, high-frequency

oscillatory ventilation 43540 (CR) bronchitis, chronic

ciprofloxacin suspension efficacy vs. co-amoxiclav tablets 252261

cutaneous hypersensitivity in smokers 491-7 Finnish National Guidelines for prevention and treat-

ment 1998-2007 297-332 infection in acute exacerbations 845-50 prevalence in Finland 798-809 promoter variation of tumour necrosis factor-alpha gene

as high risk for 752-3 (SC) bronchoalveolar lavage see bronchial alveolar lavage bronchocentric granulomatosis from Aspergillus terreus

6724 (CR) bronchodilator response in airway obstruction 630-6 bronchoscopy

fibre-optic, role in organ transplants in patients with pulmonary infections 621-9

under local anaesthesia and midazolam sedation, codeine phosphate premeditation role in 413-15

midazolam sedation for amnesia in 361-5 Briick WM 21-6 Bruggeman CA 571-8 Brun P 33-8 budesonide

cost-effectiveness in asthma 402-7 effect on lung function and asthma exacerbations 6 13-20 following steroid reversibility test in COPD 715-18 inhaled, serum leptin in children with asthma 268-71 via Turbuhaler for asthma 230-5

Burge PS 161-6 Burke CM 23644, 370 (erratum), (erratum end July issue) Byrd Jr RP 379-81

Califano C 909-l 1 Calverly PMA 161-6 Caminero J 73943 Campbell EJ 481-90 Campbell LM 23644, 370 (erratum), (erratum end July

issue) capsaicin, cough response to 58861 carbon dioxide

elimination in carbonic anhydrase deficiency 536-9 responsiveness in nocturnal hypoxaemia from COPD 79-

87 carbonic anhdyrase deficinecy, carbon dioxide elimination

in 5369 cardiopulmonary exercise testing in ankylosing spondylitis

700-8 Carlsson L 183-9

INDEX

oxygen therapy in Netherlands 46-51 peak inspiratory flow through Turbuhaler 3424 review 851-5 sleep quality, carbon dioxide responsiveness and hypox-

aemic patterns in nocturnal hypoxaemia from 79-87 spirometry and reversibility testing for patient identifica-

tion on asthma registers 903-8 steroid reversibility test plus inhaled budesonide in

715-18 thiobarbituric acid-reactive substances and hydrogen

peroxide levels in expired breath, smoking and 389-96

treadmill exercise duration and dyspnoea recovery time, effect of oxygen breathing and repeated testing 71 (I-)

treatment and exacerbations 173-9 ventilation outcomes 29&2 (L) vs. asthma mortality in emergency room 822-6 withdrawal of inhaled corticosteroids 161-6

car pulmonale, brain natriuretic peptide levels in chronic respiratory failure with 507-14

corticosteroid inhaled, for adult asthma 149-60 in asthma, salmeterol and need for 863-8 compliance in asthma 88-94 withdrawal in COPD 161-6 treatment of asthma 141-6 (L), 292-4 (L)

Couderc L-J 65-8 (CR) cough induced by low pH 58-61 Cox CA 770-8 CPAP

effects on pituitary reactivity, androgens and catechola- mines in obstructive sleep apnoea l-7

humidifier to reduce upper airway dryness 21-6 Crawford A 45460 Crompton GK 3424 Croonenborghs L 613-20 CT scan modalities showing tracheal stenosis 839-41 (CR) Cullen AB 770-8 Cuss FM 603-12 cutaneous hypersensitivity in chronic bronchitis in smokers

491-7 cystic fibrosis

nitric oxide inhalation effect on pulmonary function in 579-83

patients, prophylactic antibiotic therapy and Aspergih colonization in 835-8

cytokine production by alveolar macrophages, pentoxifyl- line effect on 52-7

D’Amato M 909-l 1 Dahl R 863-8 DahlCn I 744-51 Dauletbaev N 835-8 Davidson AC 29&l (L) Davidson AC 8-10 Davies PDO 54&5 De Brauwer EIGB 571-8 Dean G 759-62 Dent RG 794-7

Dewar MH 3424 Di Perna F 909-l 1 Diamon JJ 88-94 Diaz Nuevo G 8 162 1 Dichter JR 373-8 diens, conjugated, levels in pulmonary TB 272-6 Dirksen A 685-8 Dluhy RG 145 (L) Dodd ME 71 (L) Domingo-Salvany A 822-6 Dominino JC 552-6 Donnelly R 141-2 (L) Douze JMC 46-51 Drent M 571-8 Drobnic F 73943 Duce F 73943 Ducroix JP 208-12 Duval ELIM 435-40 (CR) Dvorin DJ 603-12 dyspnoea

and pulmonary function impairment in exposed workers 3945

recovery time in COPD, effect of oxygen breathing and repeated testing 71-3 (L)

Ebbehoj N 885-90 eformoterol via Turbuhaler in asthma 23643, 370 (erra-

tum), (erratum end July issue) Efthimiou J 689-99 eicosanoids, urinary, as marker for clinical response to

thromboxane A2 receptor antagonist in asthma 891-7 Ekberg-Jansson A 563-70 Ekstriim T 584-8 Elbek 0 349-55 Elkholy MM 202-7 Emi M 752-3 (SC) emphysema and amiodarone lung, spirometry normal-

ization in 597-600 (CR) EOLO Group 173-9 eosinophil

cationic protein, serum, and bronchial hyperresponsive- ness 589-96

percentage in pleural space, idiopathic spontaneous pneumothorax and 262-7

eosinophilic inflammation in corticosteroid-dependent asth- ma 183-9

Epardeau B 65-8 (CR) epoprostenol effect in pulmonary hypertension from

systemic sclerosis 75-8 Erikssen J 467-73 Eschenbruch C 624 (CR) exercise

-induced respiratory symptoms 734-8 : oxygen cost diagram and six-minute walking distance

810-15 exostoses, multiple hereditary, thoracic complications

217-19(CR)

Fabel H 62-70 (CR) Farouk A 202-7

INDEX

Farrer M 75-8 Faurschou P 863-8 Feder G 903-8 Ferre J 47680 Ferrer A 476-80 FEVt

effect of gestational parity in healthy women 382-8 longitudinal decline, von Willebrand factors, chronic

respiratory symptoms and 72633 fibroblast IL-l 1 production, human lung, prostaglandin Ez

role in 63742 Ficker JH 21-6 Fields-Ossorio C 379-8 1 Filicori M 869-74 fine particle fraction measurement 123-33 Finn AF 603312 Fireman E 827-34 Fish JE 788-93 Fisher KL 589-96 (CR) Fitting JW 81&15 fluticasone propionate

cost-effectiveness in asthma 402-7 effect on lung function and asthma exacerbations 6 13-20 nebulized, in severe chronic asthma 689-99 /salmeterol inhaler for steroid-dependent asthma 876-84

Folgering H 643-7 FORCE research group 23644, 370 (erratum), (erratum

end July issue) forced vital capacity fall as marker in asthma severity 277-

82 Forcina A 39945 Foresta C 869-74 formoterol-induced bronchodilation in COPD, oxitropium

bromide dose effect on 909-l 1 Foschino MP 190-5 Foster G 903-8 Fozard JL 382-8 Frachono I 65-8 (CR) Frandsen J 715-18 French Bambuterol Study Group 33-8 Frolund L 685-8 Fujita J 1 l-l 5, 113-l 8 Fyffe J 7947

G/GM-CSF causing pulmonary toxicity 65-8 (CR) Galli RL 180-2 Ganderton D (ed.) 123-33 Garcia-Aymerich J 822-6 Garcia-Rodriguez LA 709-14 Gartig S 579-83 Gemke RJBJ 43540 (CR) genetic factors in lung disease (abstracts Al-A17; Sept

issue) gentamicin intra-tracheal delivery with partial liquid

ventilation 770-8 gestational parity, effect on FEVl in healthy women 382-8 Gil& LS 648-54 Giner J 73943 Glerant JCh 208-12 Gloeckner K 498-506

Godard P 33-8, 183-9, 461-6 Gore1 N 119-22 Gram-negative bacillary carriage, oropharyngeal, in COPD

540-5 Grana JR 788-93 Grasemann H 579-83 Grief J 827-34 Griffiths C 903-8 Gross GN 603-12 Gross WI 498-506 Gruppo I.D.A. 169-72 Guarraci P 169-72 Gude F 108812 Guido P 190-5

haemodialysis, tuberculin reactivity and peripheral lym- phocyte subsets in 119-22

Hahn EG 21-6 Haku T 666-71 Hallett C 2924 (L) Hamman-rich syndrome and radiation 13640 (CR) Hanchak NA 788-93 Hancock M 72-3 (L) Hancox M 220-2 (L) Hanibuchi M 66671 Hanley ME 217-19 (CR) Harik-Khan R 382-8 Harrison JE 603-12 Hart SR 8-10 Hartopp R 552-6 Hasegawa Y 4324 (SC) Haworth CS 71 (L) Hayashi R 63742 Hedman J 589-96 Heinig JH 6 13-20 Hellmuth D 208-12 Hellstrom G 79-87 Hendrick DJ 923-7 Henriksen AH 719-25 Herjavecz I 230-5 Hermine 0 65-8 (CR) Herulf M 134-5 (SR) Heuck C 268-71 Heuvel MM van den 262-7 Heymans HSA 102-7 HFA 134a for beclomethasone inhalers in asthma 24451 high-frequency oscillatory ventilation for respiratory syn-

cytial virus bronchiolitis 435-40 (CR) Hill A 291-2 (L) Hill AT 48 l-90 Hillerdal G 349-55, 898-902 Hipp SJ 77G8 Hiraga Y A 408-12 Hirasawa M A 408-12 Hirsch Th 213-16 (SR) HIV infection, Pneumocystis carinii pneumonia, steroid

effects on surfactant levels 373-8 Hoeper MM 62-4 (CR) Holland C 75-8 Hooper G 424-31

INDEX

Hopkinson R 291-2 (L) Horne R 763-9 Hughes CR 919-22 humidifier to reduce upper airway dryness during CPAP

21-6 Hunter CJ 345-8 hydrogen peroxide levels in expired breath in COPD,

smoking and 389-96 Hyland M 515-19 hypoxaemic patterns in nocturnal hypoxaemia from COPD

79-87

Igarashi T 891-7 iloprost effects in pulmonary veno-occlusive disease 62-4

(CR) inflammatory markers in acute exacerbations of asthma

and COPD 744-51 inhalers, new formulation metered dose 167-8 interleukin-10 production by alveolar macrophages in lung

cancer 66671 interleukin-1 1 production, human lung fibroblast, prosta-

glandin Ez role in 63742 interstitial lung disease, non-granulomatous, induced spu-

tum vs. BAL for evaluation 827-34 Intrator 0 338-41 ipratropium bromide and gas exchange in COPD 222-3 (L) Ishil Y 507-14 Ishimatsu Y 138-40 (CR) Ismail MM 655-9 ISOLDE Study Group 161-6 Iwashita T 138-40 (CR)

Jacobs JA 571-8 Jager JC 779-87 Jamieson A 342-4 Jang A-S 912-18 Janson C 552-6, 74451 Janssens JP 8 1 &15 Jarad NA 1616 Jenkins SC 660-5 Jensen BN 373-8 Jensen V 885-90 Jimenez Castro D 8 162 1 Johansen JS 885-90 Johnson A 397401 Jolobe OMP 146 (L) Jones JI 42431 Jones K 515-19, 923-7 Jones P 85662 Jones RCM 919-22 Jiinsson E 798-809 Joore MA 779-87 Jorgensen N 734-8 Jounieaux V 208-12

Kadota J 138-40 (CR) Kamei T 11-15, 113-18 Kampelmacher MJ 465 1 Kampmann JP 715-18 Kaneko S 891-7

Kanstrup I-L 196-201, 885-90 Karetzky M 603-12 Kasielski M 389-96 Kato H 5369 Kauppinen R 283-9 Kawasaki Y 672-4 (CR) Kazi D 52-7 Keaney NP 75-8 ” Kearlsey N 252-61 Keicho N 752-3 (SC) Keller S 85662 Kemp J 677-84 Kemp JP 603-12 Kempe G 213-16 (SR) ketotifen in adolescent asthma 677-84 Kitagawa C 4324 (SC) Kitamura S 507-14 Kobayahsi K 6724 (CR) Kobayashi M 113-18, 63742 Kofoed-Enevoldsen A 885-90 Kijhler B 835-8 Kohno S 138840 (CR) Kolsuz M 349-55 Kontozoglou T 52-7 Koskela K 297-332 Kotaniemi J 798-809 Kramer MR 621-9 Kubin R 252-61 Kudoh S 752-3 (SC) Kumazawa A 432-4 (SC) Kuss A 252-61 Kwiatkowska S 2726

La Sala GB 869-74 lactate dehydrogenase isoenzyme analysis for pleural

effusion diagnosis in haemato-oncological patients 338841

Laforce C 603-12 Lagerstrand L 79-87 Laitinen A 445-53 Laitinen LA 297-332, 445-53, 798-809 Lammers J-WJ 4651 Lange P 333-7 Lantero S 41623 Larsen F 898-902 Larsson S 491-7 Lasch L 88-94 Laspa SL 798-809 Lawrence M 373-8 Leach C 367-9 (L) Lee M-L 83941 (CR) Lehnert G 21-6 Leidl R 779-87 Leone FT 788-93 leptin, serum, in asthma treated with inhaled budesonide

268-7 1 Let-man Y 827-34 Leroy PLJM 43540 (CR) leukotriene Ed, urinary, and bronchial hyperresponsiveness

589-96

INDEX

Massobrio M 169-72, 648-54 Mastella G 869-74 Matai R 58861 Matera MG 227-9 (E), 909-l 1 Matsubara Y 13840 (CR) Matsui S 63742 Mayordomo C 173-9 Mazzarella G 909-l 1 McDermott P 788-93 McFarlane D 82226 McLean A 3424 Mel&ant CF 46-51 Menchicchi FM 169-72 Mendelson LM 603-12 Meriste S 445-53 mesothelioma, malignant, asbestos exposure in environ-

ment and 349-55 methacholine-induced fall in FEC as marker of asthma

severity 277782 Metintas M 349-55 Metintas S 349-55 Meyer M 21-6 midazolam sedation

for amnesia in bronchoscopy 361-5 for bronchoscopy, codeine phosphate premeditation role

in 413-15 Milanowski J 245-51 Milford Ward A 481-90 Mino T 63742 Miravitiles M 173-9 Miyazaki N 891-7 Mobbs KJ 540-5 Mochizuki T 95-101 Moilanen E 589-96 Miiller M 5848 Mollers MJ 613-20 Molvig J 885-90 mometasone furoate dry powder inhaler for asthma 603-12 Montane F 33-8 Montella N 822-6 Montiel GC 523-35, 63c6 Morice AH 58-61 Morrell CH 382-8 Mtiller-Quernheim J 498-506 Murciano D 33-8 muscle function in ankylosing spondylitis 700-8 Mutlu S 349-55 Mycobacterium vaccae immunotherapy effect on TB 557-62 Mycobacterium avium-intracellulare complex, chest CT

follow-up 11-15 Myers P 1620 myocardial infarction and snoring 108-12

leukotriene modifers in adolescent asthma 677-84 LFA-1 expression, beta-agonist-induced inhibition of neu-

trophil chemotaxis, effect on 416-23 Lindberg M 5848 Little SA 202-7 Livingstone A 903-8 Lloyd-Owen SJ 454-60 Lijfdahl C-G 563-70 Lofroos A-B A 408-12 Longstaff M 290 (L) Lossos IS 338-41 Lou C 382-8 Lourens MS 102-7 Liiwhagen 0 7348, 851-5 Ludviksdottir D 552-6 Luisetti M 169-72, 648-54 Lumry W 603-12 Lundback B 798-809 Lundberg JON 134-5 (SR) Lundgren JD 373-8 lung

cancer interleukin- 10 production by alveolar macrophages in

666-71 interstitial pneumonia and 7546 (CR) disposition of inhaled drugs 123-33 disease, genetic factors (abstracts Al-A17; Sept issue) function, altitude effects on 73943

thoracentesis effect on 196-201 -specific health status measure in COPD outpatients 467-

73 squamous cell carcinoma, pulmonary alveolar proteino-

sis with 13840 (CR) lymphocyte

activation markers in blood vs. bronchial biopsies and BAL 563-70

subsets, peripheral, tuberculin reactivity in haemodialysis and 119-22

Lynch DA 217-19(CR)

Mac-l expression, beta-agonist-induced inhibition of neu- trophil chemotaxis, effect on 41623

MacPherson S 788-93 Madsen F 685-8, 863-8 Makker HK 69-70 (CR) Malerba G 648-54 Malik MA 54651 malondialdehyde levels in pulmonary TB 272-6 Maltbrek N 715-18 Mamun M 35660 Man A 827-34 Maraabini A 3945 Markson L 88-94 Markworth S 624 (CR) Marques-Magallanes JA 71-2 (L) Marran S 445-53 Marston T 445-53 Martin N 397401 Maruyama M 637-42 Massi G 169-72

Nadeem MA 54651 Nakamura Y 113-18, 138840 (CR), 413-15 Nakano H 6724(CR) Nakata K 752-3 (SC) nebuliser, ultrasound, sputum induction success with 345-8 nedocromil sodium effects on airway subepithelial tenascin

in asthma 445-53

INDEX

Nelson H 603-12 Nerin I 739943 Newman SP 3667 (L), 424-31 Nick JA 217-19 (CR) Nicolau F 173-9 Nielsen C 715-18 Nielsen LP 863-8 Nielsen TL 373-8 Nieminen MM 589-96 Nii M 11-15 Nilsson 0 563-70 nitric oxide

effects in pulmonary veno-occlusive disease 62-4 (CR) exhalation relationship to airway responsiveness and

atopy in asthma 552-6 inhalation effect on pulmonary function in cystic fibrosis

579-83 metabolites in asthma, induced sputum vs. blood

monitoring 912-18 role in nostril widening and arterial oxygenation 134-5

W Nolop KB 603-12 Norgaard M 715-18 normality criteria selection 523-35 nostril widening and arterial oxygenation 134-5 (SR) Nowak D 27226, 389-96 Nusair S 621-9

O’Brien J 689-99 O’Callaghan C 167-8 Obayashi Y 1 l-15 obstructive sleep apnoea

beta-blockers worsening of 290 (L) effects of CPAP on pituitary reactivity, androgens and

catecholamines l-7 expiratory phase role 19&5

Oddera S 416-23 Ohishi N 752-3 (SC) Ohmichi M 891-7 Ohmichi MA 408-12 Ohmoto Y 66671 Ohtsuki Y 113-18 Oka M 13840 (CR) Olsen F 196201 omega-3 and -6 fatty acid consumption in Germany, pre-

and post-unification 213-16 (SR) organ transplants, role of fibre-optic bronchoscopy in

patients with pulmonary infections 621-9 Oriols R 476-80 Ormerod LP 1620 oropharyngeal Gram-negative bacillary carriage in COPD

540-5 Ostinelli J 33-8 Otero Otero Y 108-12 Ouchi Y 222-3 (L) oxitropium bromide dose effect on formoterol-induced

bronchodilation in COPD 909-l 1 oxygen

breathing effect in COPD on treadmill exercise duration and dyspnoea recovery time 71 (L)

cost diagram and six-minute walking distance 810-15 desaturation predictors, nocturnal, in COPD 202-7 therapy for chronic bronchitis and COPD 297-332 in COPD in Netherlands 4651 long-term, compliance 333-7

Cjzdemir N 349-55

Paggiaro PL 3945 Pallares E 8 16-2 1 Pallasaho P 798-809 panbronchiolitis promoter variation of tumour necrosis

factor-alpha gene as high risk for 752-3 (SC) Pangelley J 66&5 Parameswaran K 75-8 Parashchak MR 23644, 370 (erratum), (erratum end July

issue) Partridge MR 454-60 Pate1 KR 202-7 patient

compliance in asthma 763-9, 85662 education for self-management in asthma 283-9 health beliefs in asthma 88-94

Pavord ID 345-8 peak inspiratory flow through Turbuhaler in COPD 3424 Pearlman D 603-12 Pedersen B 863-8 pentoxifylline effect on cytokine production by alveolar

macrophages 52-7 Perez G 822-6 Perez Walton IJ 81621 Perez-Gutthann S 709-14 Perez-Rodriguez E 8 1621 Perrin VL 245-51 Peterson CGB 744-51 phosphoric acid, cough response to 58861 Piasecka G 272-6 Picca V 19&5 Pieters WR 876-84 Pietinalho A 408-12 Pietras T 389-96 Pignatti PF 648-54 Pinnock H 397401 Piotrowksi W 272-6 Pitcairn GR 3667 (L) pituitary reactivity in obstructive sleep apnoea, effects of

CPAP on l-7 pleural effusion diagnosis in haemato-oncological patients,

lactate dehydrogenase isoenzyme analysis for 338-41 pleural fluid analysis in idiopathic spontaneous pneu-

mothorax 262-7 pleural TB, ADA,/ADAp ratio in 8 16-21 pleurodesis impact in malignant effusion on respiratory

function 898-902 Pneumocystis carinii pneumonia in HIV infection, steroid

effects on surfactant levels 373-8 pneumonia

community-acquired, pre-admission antibiotic effect on blood cultures 208-12

interstitial, and primary lung cancer 754-6 (CR) non-specific interstitial, clinical features 113-l 8

pneumothorax diagnosis following aspiration of pulmonary lesions

379-81 idiopathic spontaneous, pleural fluid analysis in 262-7 secondary spontaneous, blood-patch pleurodesis 4324

(SC) Pohl K 62-70 (CR) polymorphonuclear leukocyte antibacterial activity, neu-

trophil chemotaxis beta-agonist-induced inhibition, effect on 416-23

Polyzogopoulou C 52-7 Posselt H-G 835-8 Postma MJ 779-87 Postmus PE 262-7 Poulakis N 52-7 Poussa T 589-96 Pradal U 869-74 Prescott RJ 16-20 Price J 677-84 Price MJ 402-7 prostaglandin E2 role in human lung fibroblast IL-11

production 63742 Provata A 52-7 Pseudomonas aeruginosa, antibiotic therapy inhalation

chronic bronchial infection by 476-80 pulmonary alveolar proteinosis with lung squamous cell

carcinoma 13840 (CR) pulmonary damage following zinc chloride smoke exposure

885-90 pulmonary disease in lupus 95-101 pulmonary eosinophilia, tropical, diagnostic criteria 655-9 pulmonary function

in ankylosing spondylitis 700-8 in cystic fibrosis, nitric oxide inhalation effect on 579-83 impairment and dyspnoea in exposed workers 3945 tests, understanding amongst trainee doctors 35660

pulmonary hypertension from systemic sclerosis, epopros- tenol effect in 75-8

pulmonary infections, role of fibre-optic bronchoscopy in organ transplant 621-9

pulmonary lesions, pneumothorax diagnosis following aspiration of 379-8 1

pulmonary toxicity of chemotherapy and G/GM-CSF 65-8 (CR)

pulmonary veno-occlusive disease, effects of inhaled nitric oxide and aerosolized iloprost 624 (CR)

Purcell I 75-8

Quadrelli S 523-35 Quadrelli SA 630-6 Qualtrough J 245-51 Qvarfordt I 491-7

Rachelefsky G 603-12 radiation, Hamman-rich syndrome and 13640 (CR) Ramsay G 571-8 Ratjeb F 579-83 Ratner P 603-12 Raza SN 54651 Read RC 252-61, 845-50 rehabilitation for chronic bronchitis and COPD 297-332

Rephser L 603-12 respiratory disease, mild, in absence of vas deferens 869-74 respiratory failure with car pulmonale, brain natriuretic

peptide levels in 507-14 respiratory function

assessment 523-35 pleurodesis impact in malignant effusion on 898-902

respiratory muscle function in ankylosing spondylitis 700-8 respiratory sleep-related breathing disorders screening costs

45460 respiratory symptoms

chronic, von Willebrand factors and FEVl longitudinal decline 72633

exercise-induced 7348 respiratory syncytial virus bronchiolitis, high-frequency

oscillatory ventilation 43540 (CR) Resta B 190-5 Reuter M 498-506 reversibility testing for patient identification with COPD on

asthma registers 903-8 Riantawan P 700-8 Riise GC 491-7 Ringbaek T 333-7 Roberts CM 45460 Rochat T 8 10-l 5 Rodriguez M 180-2 Rodriguez-Suarez JR 108-12 Rogers TK 1367 (CR) Roig J 47680 Roland Petersen J 196201 Rollof J 491-7 Romagnoli M 183-9, 461-6 Roncoroni A 523-35 Roncoroni AJ 630-6 Rose11 A 47680 Rossi GA 41623 Roy TM 379-81 Rubi J 81621 Rutten-van Miilken MPMH 779-87 Ryan G 660-5

Saarelainen SvLaher M 689-99 Saene HKF van 540-5 Saitoh T 891-7 salmeterol

/fluticasone propionate inhaler for steroid-dependent asthma 87684

and gas exchange in COPD 222-3 (L) and need for inhaled corticosteroid in asthma 863-8 via pressurized metered dose inhaler or Accuhaler in

asthma 23643, 370 (erratum), (erratum end July issue)

vs. bambuterol for nocturnal symptoms in asthma 33-8 Sampol G 47680 Sanchez Hernandez JJ 8 162 1 Sanchez-Agudo L 173-9 Sandek K 79-87 sarcoidosis

familial, in Finland and Japan 408-12 induced sputum vs. BAL for evaluation 827-34

Sato H 413-15 Sato M 4324 (SC) Satoh T 95-101 Scarpelli F 19&5 Schattenkerk J 373-S Schayck CP van 643-7 Schliisser NJJ 876-84 Schmit JL 208-12 Schnabel A 498-506 Schouten JP 102-7 Schulz A 624 6724 (CR) Schwarz MI 217-19 (CR) Schwarz Y 827-34 Seale JP 141-2 (L) Segal AT 603-12 Segti J-L 173-9 Selner JC 603-12 Selroos 0 A 408-12 Senderovitz T 7 15-l 8 Serrano A 230-5 Settipane GA 603-12 Shaffer TH 77&8 Shaw 149-60 Shelhamer J 373-8 Shima K 432-4 (SC) Shimokata K 4324 (SC) Shishido S 672-4 (CR) Sillatsu H 445-53 Silvestri M 41623 Simmons JL 27-32 Singh M 552-6 Singh Marlowe G 903-8 Sintonen H 283-9 Siracusa A 39-45 sleep

quality in nocturnal hypoxaemia from COPD 79-87 -related breathing disorders screening costs in snorers

454-60 see also obstructive sleep apnoea

Smit HJM 262-7 smoking

cutaneous hypersensitivity in chronic bronchitis 491-7 prevention by dentists 297-332 and thiobarbituric acid-reactive substances/hydrogen

peroxide levels in expired breath in COPD 389-96 Snell NJC (ed.) 123-33 ’ snoring

and myocardial infarction 108-12 respiratory sleep-related breathing disorders screening

costs 454-60 Sone S 666-71 Sovijarvi ARA 798-809 Spacehaler, beclomethasone dipropionate targeting to

lungs of asthmatics with 424-3 1 spirometry

normalization in emphysema and amiodarone lung 597- 600 (CR)

office 685-8 for patient identification with COPD on asthma registers

903-8

reference values 523-35 and tracheal auscultation agreement in bronchial respon-

siveness in asthma 102-7 volume calibration in 643-7

Sprikkelman AB 102-7 sputum induction

success with ultrasonic nebuliser 345-8 vs. BAL for evaluation of sarcoidosis and non-granulo-

matous interstitial lung disease 827-34 squamous cell carcinoma, lung, pulmonary alveolar protei-

nosis with 138-40 (CR) Stableforth D 291-2 (L) Sdlenheim G 744-51 Stampone P 27-32 Stanford C 5526 Stanford J 552-6 Star LM van der 643-7 Stavem K 467-73 Steed KP 424-31 Steinmetz K-O 876-84 Stelianides S 65-8 (CR) Stern M 65-8 (CR) steroid

effects on surfactant levels, Pneumocystis carinii pneu- monia in HIV infection, 373-8

reduction by nebulized fluticasone propionate 689-99 reversibility test plus inhaled budesonide in COPD

715-18 Stockley RA 481-90 Storer TW 71-2 (L) Sturrock RD 70&8 Sue-Chu M 719-25 Suemitsu I 11-15, 113-18 Sugiyama E 63742 Sugiyama Y 507-14 Sfikti Sever M 119-22 Summers RL 18&2 Sunderland D 54&5 Sunyer J 822-6 surfactant levels, Pneumocystis carinii pneumonia in HIV

infection, steroid effects on 373-8 Suzuki Y 66671 systemic lupus erythematosus, clinical and laboratory

features 95-101 systemic sclerosis, epoprostenol effect in pulmonary hyper-

tension from 75-8 Szefler SJ 1424 (L)

Taguchi Y 752-3 (SC) Takahara J 11-15, 113-18 Takeuchi E 66671 Taki H 637-42 Taki K 5369 Talini D 39-45 Tanaka H 891-7 Tarodo de la Fuente P 183-9 Tassiopoulou A 52-7 Taylor IK 75-8 tenascin in asthma, airway subepithelial, albuterol and

nedocromil sodium effects on 445-53

INDEX

Ven AJAM van der 571-S Venge P 74451 ventilation outcomes in COPD 290-2 (L) ventilatory function in healthy Pakistanis 546-5 1 Vermerie P 856-62 Vestbo J 715-18 Viegi G 39945 Vignola AM 461-6 Vilkka V 28339 Viskum K 333-7 Vitalograph-R belows spirometer 685-8 Vittrup Jensen B 196201 volume calibration in spirometry 643-7 von Willebrand factors, chronic respiratory symptoms and

FEVi longitudinal decline 72633 Vught AJ van 43540 (CR)

Teramoto S 222-3 (L), 891-7 theophylline in adolescent asthma 677-84 thiobarbituric acid-reactive substances levels in expired

breath in COPD, smoking and 389-96 Thomson NC 202-7 thoracentesis effect on lung function and transthoracic

electric bioimpedance 196201 thromboxane A2 receptor antagonist in asthma, urinary

eicosanoids as marker for clinical response to 891-7 Thwaites RMA 402-7 Togores B 73943 Tokunaga K 752-3 (SC) Topilsky I 827-34 Topilsky M 827-34 Torres A 252-61 tracheal auscultation and spirometry agreement in bron-

chial responsiveness in asthma 102-7 tracheal stenosis shown by different CT scans 839941 (CR) transthoracic electric bioimpedance, thoracentesis effect on

196201 Treacher DF 290-l (L) treadmill exercise duration and dyspnoea recovery time in

COPD, effect of oxygen breathing and repeated testing 71 (L)

Troncon MG 709-14 tropical pulmonary eosinophilia, diagnostic criteria 655-9 Tsukioka T 413-15 Tsunezuka Y 413-15 tuberculin reactivity and peripheral lymphocyte subsets in

haemodialysis 119-22 tuberculosis

badgers and cattle 72-3 (L) bovine, transmission routes 220-2 (L) effects of immunotherapy with Mycobacteria vaccae 55742 evidence-based dosage guidelines 75962 pleural, ADAi/ADAp ratio in 81621 pulmonary, conjugated diens and malondialdehyde levels

27226 Tukiainan H 283-9 tumour necrosis factor-alpha gene, promoter variation

752-3 (SC) Turbitt ML 23644, 370 (erratum), (erratum end July issue) Turbuhaler, peak inspiratory flow in COPD through 3424 Turk S 119-22

&gun I 349-55 Ukale V 898-902 Ulrik CS 685-8 ultrasonic nebuliser, sputum induction success with 345-8 Upchurch FC 424-31 urinary eicosanoids as marker for clinical response to

thromboxane A2 receptor antagonist in asthma 891-7

Vachier I 461-6 Valentini E 552-6 Vallano A 47680 Van Genugten MLL 779-87 Van Kesteren RG 4651 vas deferens absence, congenital, mild respiratory disease in

869-74

Wagenaar SjSc 571-8 Wagner TOF 835-8 Wallaert B 33-8 Wanderer A 603-12 Wang Y-T 277-82 Ward R 345-8 Wardlow AJ 345-8 Watanabe A 432-4 (SC) Watanabe Y 413-l 5 Watson SA 23644, 370 (erratum), (erratum end July issue) Webb AK 71 (L) Wedzicha J 903-8 Wedzicha JA 161-6 Wee1 C van 643-7 Wegener’s granulomatosis, bronchoalveolar lavage cell

profiles in 498506 Weitzberg E 134-5 (SR) Wennlund A l-7 Westbroek J 689-99 Wharton SP 136-7 (CR) Widstriim 0 898-902 Wiessemann HG 579-83 Wiest GH 21-6 Wilcke JTR 863-8 Wildman M 291-2 (L) Williams TJ 361-5 Wise RA 382-8 Wolf M 835-8 Wolfson MR 770-8 Wolthers OD 268-71 Woltmann G 345-8 Wong CH 58-61 Woodward L-A 180-2 Wright D 919-22 Wynne HJ 4651

Yamadori I 113-18 Yamaji Y 113-18 Yamamoto M 4324 (SC) Yamashita N 637-42 Yanagawa H 66671 Yano S 6724 (CR) Yildiz A 119-22

INDEX

Yildiz P 119-22 Yoshida I 53&9 Yoshinaga M 13840 (CR) Yoshinouchi T 113-18 Young P 397401 Yousef Z 794-7

Zamarr6n C 108-12 Zerahn B 196-201, 885-90 Zieba M 272-6 zinc chloride smoke exposure, pulmonary damage 885-90 Zink-Wohlfart C 62-4 (CR)